Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.59 |
| ▸ | POLA1 | P09884 | 2/20 | 0.54 |
| ▸ | CDK2 | P24941 | 6/20 | 0.48 |
| ▸ | CDK1 | P06493 | 5/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | PI4KA | P42356 | 2/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9119 | 1.00 | PDPK1 (0.59) | PDPK1GDAPOLA1CDK2CDK1 | |
| SCHEMBL14977062 | 0.84 | PDPK1 (0.61) | PDPK1GDAPOLA1CDK2CDK1 | |
| SCHEMBL28274636 | 0.83 | PDPK1 (0.56) | PDPK1GDAPOLA1CDK2CDK1 | |
| SCHEMBL16145922 | 0.81 | POLA1 (0.55) | PDPK1GDAPOLA1CDK2CDK1 | |
| SCHEMBL11876697 | 0.80 | XDH (0.67) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL14938904 | 0.79 | GDA (0.54) | PDPK1GDAPOLA1XDHPI4KA | |
| SCHEMBL16146953 | 0.79 | POLA1 (0.56) | PDPK1GDAPOLA1CDK2CDK1 | |
| SCHEMBL2730455 | 0.79 | PDPK1 (0.56) | PDPK1GDAPOLA1CDK2CDK1 | |
| SCHEMBL377763 | 0.79 | CDK2 (0.48) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL28387743 | 0.78 | PDPK1 (0.54) | PDPK1GDAPOLA1CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3419665-B1 | TREATMENT METHODS FOR FIBROSIS TARGETING SMOC2 | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-10-30 | — | — | EP | claimed |
| EP-3843845-B1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIV MASSACHUSETTS (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705462-A2 | COMPOSITIONS AND METHODS FOR ENGINEERING MATURE IPSC-DERIVED AND ESC-DERIVED HEPATOCYTES | Duke University (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4685144-A1 | NON-FLUORESCENT COMPOUND AND USES THEREOF | SFC Co., Ltd. (KR) | 2026-01-28 | — | — | EP | disclosed |
| US-20260015655-A1 | COMPOUNDS AND THEIR APPLICATIONS | SFC CO., LTD. (KR) | 2026-01-15 | — | — | US | disclosed |
| EP-4674845-A1 | NOVEL COMPOUND AND USE THEREOF | SFC Co., Ltd. (KR) | 2026-01-07 | — | — | EP | disclosed |
| EP-4649147-A2 | TYPE II CAS PROTEINS AND APPLICATIONS THEREOF | Alia Therapeutics Srl (IT) | 2025-11-19 | — | — | EP | disclosed |
| EP-3368089-B1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA INC (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4637842-A1 | INHIBITION OF ZBTB7A | Icahn School of Medicine at Mount Sinai (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4630557-A1 | INHIBITORY NUCLEIC ACIDS AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2025-10-15 | — | — | EP | disclosed |
| WO-2022081693-A1 | COMPOSITIONS AND METHODS TARGETING CIRC2082 FOR THE TREATMENT OF CANCER | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-114375300-A | Universal donor cell | 克里斯珀医疗股份公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114375194-A | Treatment of angiopoietin-like 7(ANGPTL7) -related diseases | 艾姆皮瑞克公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114364791-A | Universal donor cell | 克里斯珀医疗股份公司 | 2022-04-15 | — | — | CN | disclosed |
| WO-2022076901-A1 | NOVEL TARGETS FOR REACTIVATION OF PRADER-WILLI SYNDROME-ASSOCIATED GENES | DUKE UNIVERSITY (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022070107-A1 | MATERIALS AND METHODS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CRISPR THERAPEUTICS AG (CH) | 2022-04-07 | — | — | WO | disclosed |
| EP-3976594-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | The Schepens Eye Research Institute, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-107530399-B | Effective delivery of therapeutic molecules in vitro and in vivo | 马萨诸塞眼科耳科诊所 | 2022-03-18 | — | — | CN | disclosed |
| CN-114206849-A | Therapeutic methods for treating non-infectious ocular immunoinflammatory disorders | 斯格本斯眼科研究所有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3946629-A1 | THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS | University Of Massachusetts (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015655-A1 | COMPOUNDS AND THEIR APPLICATIONS | OGA, NSUN3, CDK10 | PDPK1 4063/4885GDA 3900/4885POLA1 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.